HuMax-CD20 ofatumumab: Phase II started

The partners began a double-blind, placebo-controlled, international Phase II trial to evaluate 100, 300 or 700 mg of IV ofatumumab in about 324 patients. The trial start triggers a DKK29 million ($6....